OrthoLogic President/COO George Oram puts new face on management of embattled firm.
This article was originally published in The Gray Sheet
Executive Summary
ORTHOLOGIC PRESIDENT/COO GEORGE ORAM PUTS NEW FACE ON MANAGEMENT of the bone growth stimulator firm as it prepares to respond to two shareholder lawsuits and an inquiry by the National Association of Securities Dealers. An OrthoLogic board member since 1992 and president and CEO of pharmaceutical firm Fibromed, Oram, 48, will take over "day-to-day" responsibility of OrthoLogic from company founder Allan Weinstein. Weinstein, who will retain the titles of chairman and CEO, is a co-defendant in the shareholder suits, and his recent trades of OrthoLogic stock are likely to be reviewed in the NASD inquiry.
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.